Doc code: IDS

Doc description: Information Disclosure Statement (IDS) Filed

10589410 - GAJ (621) Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10589410	
	Filing Date		2007-06-04	
	First Named Inventor Valen		lentina Molteni	
	Art Unit		1621	
	Examiner Name	Zucke	ker, Paul A.	
	Attorney Docket Number		PAT033827-US-PCT	

	U.S.PATENTS									
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D)ate	Name of Pate of cited Docu	entee or Applicant ment	Relev	s,Columns,Lines where vant Passages or Relev es Appear	
	1	5110348		1992-05	i-05	Hopwood				
If you wis	f you wish to add additional U.S. Patent citation information please click the Add button.									
			U.S.P	ATENT	APPLI	CATION PUBI	LICATIONS			
Examiner Initial*	Cite N	Publication Number	Kind Code ¹	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant ment	Relev	s,Columns,Lines where vant Passages or Relev es Appear	
	1									
If you wis	h to ad	d additional U.S. Publi	shed Ap	plication	citation	n information p	olease click the Add	butto	on.	
				FOREIG	SN PAT	ENT DOCUM	ENTS			
Examiner Initial*		Foreign Document Number ³	Country Code ² i		Kind Code ⁴	Publication Date	Name of Patentee Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T 5
	1	DE 1185194	DE			1965-01-14	Nippon Shinyaku C	o. Ltd.		
	2	1340750A1 EP 1 84750AT	EP			2003-09-03	Yamanouchi			
	3	JP 11001456A	JP			1999-01-06	Ohtsuka			

INFORMAT	ION	DISCL	OSURE
STATEMEN	IT B	Y APPI	LICANT

(Not for submission under 37 CFR 1.99)

Application Number		10589410	10589410 - GAU: 1621
Filing Date		2007-06-04	
First Named Inventor	Valen	tina Molteni	
Art Unit		1621	
Examiner Name	Zucke	er, Paul A.	
Attorney Docket Number		PAT033827-L	S-PCT

	4	JP 07258224A	JP			Daiichi Seiyaku		
	5	JP 56083458A	JP			Hodagaya Chem.		
	6	CH 516523A	СН			Sogespar		
	7	GB 1236091A	GB			Sogespar		
If you wis	h to ac	dd additional Foreign P	atent Document	citation	information pl	ease click the Add buttor	า	
			NON-PATE	NT LITE	RATURE DO	CUMENTS		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						
	1	EVANS et al., "Some substituted phenylalkanoic acids and N-substituted malonailic, succinanillic, and anilinoalkanoic acids as potential antiinflammatory agents.", Journal of Medicinal Chemistry, Vol. 12, No. 6, pages 1006-1010, 1969						
	2	LARIZZA A., "N-aryl-N-aroylamino acid derivatives.", Journal of Medicinal Chemistry, Vol. 13, No. 5, pages 1019-1020, 1970						
	3	CAO et al., "Antidiabetic Action of a Liver X Receptor Agonist Mediated By Inhibition of Hepatic Gluconeogenesis", Journal of Biological Chemistry, Vol. 278, pages 1131-1136, 2003						
	4	CAO et al., "Liver X Receptors as Potential Therapeutic Targets for Multiple Diseases", Drug News Perspect., Vol. 17, pages 35-41, 2004						
	5					nt FRET Assays to Ultra-Hig evelopment Technologies, \		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10589410	10589410 - GAU: 1621
Filing Date		2007-06-04	
First Named Inventor	Valen	tina Molteni	
Art Unit		1621	
Examiner Name	Zucke	er, Paul A.	
Attorney Docket Number		PAT033827-U	S-PCT

6	COLLINS et al., "Identification of a Nonsteroidal Liver X Receptor Agonist through Parallel Array Synthesis of Tertiary Amines", Journal of Medicinal Chemistry, Vol. 45, pages 1963-1966, 2002	
7	FOWLER et al., "Liver X Receptor Activators Display Anti-Inflammatory Activity in Irritant and Allergic Contact Dermatitis Models: Liver-X-Receptor-Specific Inhibition of Inflammation and Primary Cytokine Production", J Invest Dermatol., Vol 120, pages 246-255, 2003	
8	JAYE, MICHEAL, "LXR agonists for the treatment of atherosclerosis", Current Opinion in Investigational Drugs, Vol. 4, pages 1053-1058, 2003	
9	JOSEPH et al., "Synthetic LXR ligand inhibits the development of atherosclerosis in mice", PNAS, Vol. 99, pages 7604-7609, 2002	
10	JOSEPG et al., "Reciprocal regulation of inflammation and lipid metabolism by liver X receptors", Nature Medicine, Vol. 9, pages 213-219, 2003	
11	JOSEPH et al., "LXRs: new therapeutic targets in atherosclerosis?", Current Opinion in Pharmacology, Vol. 3, pages 192–197, 2003	
12	LAFITTE et al., "Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue", PNAS, Vol. 100, pages 5419-5424, 2003	
13	LEHMANN et al., "Activation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway", Journal of Biological Chemistry, Vol. 272, pages 3137-3140, 1997	
14	REPA et al., "Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta", GENES & DEVELOPMENT, Vol. 14, pages 2819–2830, 2000	
15	SCHULTZ et al., "Role of LXRs in control of lipogenesis", GENES & DEVELOPMENT, Vol. 14, pages 2831–2838, 2000	
16	SPENCER et al., "Pharmacophore Analysis of the Nuclear Oxysterol Receptor LXRalpha", Journal of Medicinal Chemistry, Vol. 44, pages 886-897, 2001	

INFORMATION	DISCLOSURE
STATEMENT B	Y APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10589410	10589410 - GAU: 1621		
Filing Date		2007-06-04			
First Named Inventor	Valen	tina Molteni			
Art Unit		1621			
Examiner Name	Zucke	er, Paul A.			
Attorney Docket Number		PAT033827-U	S-PCT		

	17	TANGIRALLA et al., "Identification of macrophage liver X receptors as inhibitors of atherosclerosis", PNAS, Vol. 99, pages 11896-11901, 2002					
	18	TERASAKA et al., "T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice", FEBS Letters, Vol. 536, pages 6-11, 2003					
	19	TONTONOZ et al., "Liver X Receptor Signaling Pathways in Cardiovascular Disease", Mol. Endocrinol., Vol. 17, pages 985–993, 2003					
If you wisl	n to ac	l additional non-patent lite	rature document citation information p	lease click the Add b	putton		
			EXAMINER SIGNATURE				
Examiner Signature /Paul Zucker/ Date Considered 04/19/2010							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							
¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.							